Commentary on in-transit lymph node metastases in breast cancer: A possible source of local recurrence after Sentinel Node procedure

Journal of Clinical Pathology

Volumn 61, Issue 12, 2008, Pages 1233-1235

  Cserni, Gábor ^a  

^a BÁCS KISKUN COUNTY TEACHING HOSPITAL   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; BREAST CARCINOMA; BREAST SURGERY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; HUMAN; IN-TRANSIT METASTASIS; ISOTOPE LABELING; LYMPH NODE METASTASIS; MAMMOGRAPHY; NOTE; PRIORITY JOURNAL; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; SENTINEL LYMPH NODE BIOPSY;

EID: 57549115451     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2008.060848     Document Type: Note

References (28)

1. van Deurzen CH, Borgstein PJ, van Diest PJ. In-transit lymph node metastases in breast cancer: a possible source of local recurrence after sentinel node procedure. J Clin Pathol 2008;61:1314-16.
2. Greene FL, Page DL, Fleming ID, et al, eds. AJCC cancer staging handbook - TNM classification of malignant tumors, 6th edn. New York: Wiley, 2002.
3. Gershenwald JE, Ross MI, Buzaid AC. Staging systems for cutaneous melanoma. In: Thompson JF, Morton DL, Kroon BBR, eds. Textbook of melanoma. London: Martin Dunitz, 2004:164-80.
4. Massi D, Puig S, Franchi A, et al. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study. J Clin Pathol 2006;59:166-73.
5. Vleugel MM, Bos R, van der Groep P, et al. Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol 2004;57:746-51.
6. van der Schaft DW, Pauwels P, Hulsmans S, et al. Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett 2007;254:128-36.
7. Eccles S, Paon L, Sleeman J. Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms. Clin Exp Metastasis 2007;24:619-36.
8. Viale G, Zurrida S, Maiorano E, et al. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer 2005;103:492- 500.
9. Degnim AC, Griffith KA, Sabel MS, et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer 2003;98:2307-15.
10. Pinder SE, Ellis IO, Galea M, et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large series with long-term follow-up. Histopathology 1994;24:41-7.
11. Tot T. Clinical relevance of the distribution of the lesions in 500 consecutive breast cancer cases documented in large-format histologic sections. Cancer 2007;110:2551-60.
12. Cserni G. Pathological evaluation of sentinel lymph nodes. Surg Oncol Clin N Am 2007;16:17-34.
13. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 2006;106:4-16.
14. Cserni G, Rajtár M, Boross G. Blue nodes left behind after vital blue dye-guided axillary sentinel node biopsy in breast cancer patients. Jpn J Clin Oncol 2000;30:263-6.
15. Bleiweiss IJ. Sentinel lymph nodes in breast cancer after 10 years: rethinking basic principles. Lancet Oncol 2006;7:686-92.
16. Cserni G. What is a positive sentinel lymph node in a breast cancer patient? A practical approach. Breast 2007;16:152-60.
17. Cserni G. Mapping metastases in sentinel lymph nodes of breast cancer. Am J Clin Pathol 2000;113:351-4.
18. Greenall MJ. Why I favour axillary node sampling in the management of breast cancer. Eur J Surg Oncol 1995;21:2-5.
19. Cserni, G. Estimating the overlap between sentinel lymph nodes and axillary node samples in breast cancer. Pathol Oncol Res 1999;5:129-33.
20. Macmillan RD, Barbera D, Hadjiminas DJ, et al. Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. results of a prospective comparison study. Eur J Cancer 2001;37:1076-80.
21. Cserni G. Nodal staging of colorectal carcinomas and sentinel nodes. J Clin Pathol 2003;56:327-35.
22. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
23. Cserni G, Rajtár M, Boross G, et al. Comparison of vital dye-guided lymphatic mapping and dye plus gamma probe-guided sentinel node biopsy in breast cancer. World J Surg 2002;26:592-7.
24. Benson JR, della Rovere GQ, Axilla Management Consensus Group. Management of the axilla in women with breast cancer. Lancet Oncol 2007;8:331-48.
25. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-401.
26. Intra M, Garcia-Etienne CA, Renne G, et al. When sentinel lymph node is intramammary. Ann Surg Oncol 2008;15:1304-8.
27. Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 2006;59:729-35.
28. Cserni G. How to improve low lymph node recovery rates from axillary clearance specimens of breast cancer. A short-term audit. J Clin Pathol 1998;51:846-9.